secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zenas BioPharma, Inc. (ZBIO)
CIK:        0001953926
Form:       8-K
Filed at:   2025-10-08T23:59:59+00:00
Accession:  0001104659-25-097663
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 2.02, 8.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zenas licenses three autoimmune candidates from InnoCare; raises $120M in PIPE
------------------------------------------------------------------------------

- License grants Zenas rights to orelabrutinib (BTK inhibitor) for MS globally and non-oncology indications outside Greater China & SE Asia.
- Also obtains worldwide rights to ZB021 (oral IL-17AA/AF inhibitor) and ZB022 (brain-penetrant TYK2 inhibitor) excluding Greater China & SE Asia.
- Upfront consideration: $35M cash + 5M shares (~10.6% of ZBIO outstanding); additional near-term milestones up to $65M cash + 2M shares.
- Potential milestones total up to $1.4B across orelabrutinib ($723M), ZB021 ($656M), and ZB022 ($656M); royalties range high-single to high-teens.
- PIPE raises ~$120M gross at $19.00 (institutional) and $20.85 (directors/officers) per share; estimated pro forma cash $302M (Sept 30, 2025) funds ops into Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1953926/000110465925097663/0001104659-25-097663-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1953926/000110465925097663/tm2528075d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-097663

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer